🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Placebo via ELLIPTA

Found 26 matching trials

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

PHASE2

This is a randomized, placebo-controlled, 2-period crossover, escalating re...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-02-09

Trial ID

NCT02991859

Treatments Being Tested

Fluticasone furoate (FF) Dry Powder Inhaler Fluticasone propionate (FP) Dry Powder Inhaler Budesonide (BUD) Turbuhaler Placebo (ELLIPTA or DISKUS)

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

PHASE2

This study will evaluate the efficacy and safety data of AZD8871 in patient...

Status

Completed

Location

Research Site

Start Date

2018-10-10

Trial ID

NCT03645434

Treatments Being Tested

AZD8871 Anoro® Ellipta®

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This randomized, cross over study aims to find out the benefits of deliveri...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-09-20

Trial ID

NCT03227445

Treatments Being Tested

ELLIPTA placebo DPI DISKUS placebo DPI HandiHaler placebo DPI Inhaler preference questionnaires

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to compare in COPD patients naïve to DPIs, the...

Status

Completed

Location

Novartis Investigative Site

Start Date

2015-09

Trial ID

NCT02551224

Treatments Being Tested

Patient preference questionnaire

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

PHASE2

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-01-25

Trial ID

NCT03012061

Treatments Being Tested

Placebo UMEC Fluticasone Furoate Albuterol/salbutamol

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

COPD is characterized by an airflow limitation, which is not fully reversib...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-16

Trial ID

NCT03034915

Treatments Being Tested

UMEC/VI 62.5/25 mcg via ELLIPTA UMEC 62.5 mcg via ELLIPTA Salmeterol 50 mcg via DISKUS Placebo via ELLIPTA Placebo via DISKUS

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

PHASE4

Asthma is a chronic inflammatory disease of airways and lungs that results ...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-18

Trial ID

NCT03478657

Treatments Being Tested

Placebo DPI ELLIPTA DPI Ease of use questionnaires

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The primary purpose of this study is to assess the equivalence of closed tr...

Status

Withdrawn

Location

GSK Investigational Site

Start Date

2016-06

Trial ID

NCT02731846

Treatments Being Tested

Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg Fluticasone furoate 100 mcg + Vilanterol 25 mcg Umeclidinium 62.5 mcg Placebo ELLIPTA inhaler Albuterol/Salbutamol

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

PHASE3

Inhaled corticosteroids (ICS) have a number of known class effects includin...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-10-09

Trial ID

NCT02483975

Treatments Being Tested

FF Placebo Montelukast Albuterol/Salbutamol

Previous Next